2018

1. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

   The Lancet Neurology, Vol. 17, Núm. 5, pp. 405-415